#
  • Stadhouderskade 5 Amsterdam, AM 1054 ES , Holland

Investments

Renfield equity fund 2016 Investments


Edwards Lifesciences (NYSE:EW)

Status: Realised
Bought In : 10th March 2016 at $87.63 per share
Sold Out : 30th September 2016 $120.56

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Company conducts operations around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company's products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.